AbbVie Inc. (ABBV)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Net revenues | 15,423 | 13,343 | 14,460 | 14,462 |
| Selling, general and administrative | 3,253 | 3,293 | 4,205 | 3,377 |
| Research and development | 2,131 | 2,067 | 2,130 | 1,948 |
| Acquired ipr&d and milestones | 823 | 248 | 82 | 937 |
| Other operating income | 24 | - | - | - |
| Cost of products sold | 4,346 | 4,002 | 4,212 | 4,202 |
| Total operating costs and expenses | 10,529 | 9,610 | 10,629 | 10,464 |
| Operating earnings | 4,894 | 3,733 | 3,831 | 3,998 |
| Interest expense, net | -678 | -627 | -591 | -506 |
| Net foreign exchange loss | -23 | -4 | 3 | -1 |
| Other expense, net | -2,639 | -1,441 | -1,159 | -1,345 |
| Earnings before income tax expense | 1,554 | 1,661 | 2,084 | 2,146 |
| Income tax expense | 613 | 372 | 520 | 773 |
| Net earnings | 941 | 1,289 | 1,564 | 1,373 |
| Net earnings attributable to noncontrolling interest | 3 | 3 | 3 | 3 |
| Net earnings attributable to abbvie inc | 938 | 1,286 | 1,561 | 1,370 |
| Basic earnings per share (in dollars per share) | 0.52 | 0.72 | 0.88 | 0.77 |
| Diluted earnings per share (in dollars per share) | 0.52 | 0.72 | 0.88 | 0.77 |
| Weighted-average basic shares outstanding (in shares) | 1,768,000,000 | 1,768,000,000 | 1,769,000,000 | 1,768,000,000 |
| Weighted-average diluted shares outstanding (in shares) | 1,771,000,000 | 1,772,000,000 | 1,772,000,000 | 1,771,000,000 |